No Data
Sichuan Kelun Pharmaceutical (002422.SZ): The employee stock ownership plan shares were sold out in 2022.
On December 19, Gelonghui reported that Sichuan Kelun Pharmaceutical (002422.SZ) announced that on October 25, 2024, the company received the "Securities Transfer Registration Confirmation" issued by the Shenzhen Branch of China Securities Depository and Clearing Corporation Limited. The non-trade transfer of stocks that met the unlocking conditions for the second unlocking period of the 2022 employee stock ownership plan has been completed, with a total of 1.502 million shares transferred, accounting for 0.0938% of the company's total equity at that time. The stocks held in this employee stock ownership plan account, except for the aforementioned 3.008 million shares that were non-trade transferred to the holder's securities account that met the unlocking conditions.
Sichuan Kelun Pharmaceutical (002422.SZ): Some products are planned to be awarded in centralized procurement.
On December 13, Gelonghui reported that Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ) announced that on December 12, 2024, it and its subsidiaries participated in the bidding organized by the Joint Procurement Office for the tenth batch of national centralized procurement of Pharmaceuticals. The company's products are expected to win the bidding for this centralized procurement.
Here's Why Sichuan Kelun Pharmaceutical (SZSE:002422) Has Caught The Eye Of Investors
Sichuan Kelun Pharmaceutical Gets China Clinical Trial Nod for Anti-Tumor Drug
Express News | Sichuan Kelun Pharmaceutica Says Five Company Products Include in China Drug Catalog
Sichuan Kelun Pharmaceutical (002422.SZ) pharmaceuticals included in the national medical insurance catalog.
sichuan kelun pharmaceutical (002422.SZ) announced that on November 28, 2024, the National Medical Insurance Administration and the Ministry of Human Resources...
Why Investors Shouldn't Be Surprised By Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E
